Hepatitis C virus (HCV) is the predominant etiologic agent of posttransfusion non-A, non-B hepatitis, characterized by undulating elevation of alanine aminotransferase (ALT) and chronic liver disease. A commercial enzyme-linked immunosorbent assay detected antibodies to HCV (anti-HCV) in 11 specimens among 101 nontransfusable plasma units obtained from asymptomatic, volunteer blood donors with elevated levels of ALT. Using a combined reverse-transcription polymerase chain reaction (RT-PCR) assay developed by us, HCV RNA was detected in 0.6 ml of plasma from 8 of 11 (73%) of the anti-HCV-positive but in none of the 90 anti-HCV-negative specimens. The relatively low concentration of HCV RNA could be detected in the remaining three anti-HCV-positive specimens when 2.4 ml of plasma was analyzed. The plasma concentration of virions was estimated to range from 102 to 5 X 107/ml. Direct sequencing performed on the PCR-amplified HCV cDNAs (210 base pairs) from three specimens revealed heterogeneity between 2.5 and 8.6% at the nucleotide level and < 4% at the amino acid level. Our findings demonstrate that RT-PCR can be performed with 2.4 ml of plasma, providing an assay for the direct detection of HCV RNA and confirming the existence of an asymptomatic carrier state for HCV infection in the apparently healthy anti-HCV-positive donors. (J. Clin.
Introduction
Non-A, non-B hepatitis (NANBH)' accounts for > 90% of posttransfusion hepatitis cases, with an estimated incidence of 1-10% after blood transfusions in the United States (1). Ap- 1 . Abbreviations used in this paper: ALT, alanine aminotransferase;
anti-HCV, antibodies to HCV; CH-HCV, chimpanzee-derived HCV; HBc, hepatitis B core antigen; HBsAg, hepatitis B surface antigen; HBV and HCV, hepatitis B and C viruses; M-MLV, Moloney murine leukemia virus; NANBH, non-A, non-B hepatitis; PCR, polymerase chain reaction; RIBA, recombinant immunoblot assay; RT, reverse transcription.
proximately 50% of infected transfusion recipients develop biochemical evidence of chronic hepatitis, and -20% of recipients with chronic hepatitis subsequently develop histologic evidence of liver cirrhosis (2) . Although NANBH was first described in association with blood transfusions, surveillance data from the Centers for Disease Control showed that only 5-10% of patients with NANBH have a history of blood transfusion (3) .
A cDNA of the RNA genome of hepatitis C virus (HCV) has recently been cloned from an infected chimpanzee (CH-HCV) which developed NANBH after inoculation with a contaminated human factor VIII concentrate (4) . Studies on the genome of HCV revealed positive-stranded RNA of -10,000 nucleotides with distant homology to the Flaviviridae (4). Expression of a recombinant HCV fusion protein in yeast led to the development of immunoassays for antibodies to HCV (anti-HCV) in plasma and serum (5) . Seroepidemiologic studies in the United States, Japan, and Europe revealed that 80-100% of patients with chronic posttransfusion NANBH have detectable levels of circulating anti-HCV (5) (6) (7) (8) (9) . These data support the identification of HCV as the predominant agent of chronic posttransfusion NANBH worldwide (10) . However, the frequency of detectable anti-HCV in acute resolving NANBH infections was much lower, ranging from 15 to 60% with a mean delay to seroconversion of almost 6 mo after transfusion (3, 10) . These data emphasize the need for sensitive, direct assays for viral markers. In view of the expected low titers of HCV antigens in infected individuals, antigen assays are likely to have inherent limitations of sensitivity. Therefore, we employed reverse transcription (RT) in combination with polymerase chain reaction amplification (RT-PCR) as a sensitive direct assay for the detection of HCV RNA in plasma.
We report here the prevalence of HCV RNA in plasma from asymptomatic, volunteer blood donors with elevated alanine aminotransferase (ALT), and its correlation with the presence of anti-HCV, hepatitis B surface antigen (HBsAg), and antibodies to hepatitis B core antigen (anti-HBc). The titers of HCV cDNA were determined by serial dilution endpoint titration and PCR detection to obtain quantitative information about the virus load in infected individuals. Amplified HCV cDNAs from the three plasma specimens with the highest virus titer were directly sequenced and compared with the CH-HCV cDNA sequence to determine the degree of genome heterogeneity among different HCV isolates. rejected owing to elevated ALT levels ranging from 68 to > 700 IU/ liter (reference range from 2 to 54 IU/liter). During this period, Irwin Memorial Blood Centers collected a total of 30,184 donor units, of which a total of 198 were rejected because of elevated ALT. We failed to obtain the remaining 97 ALT-elevated units during this period owing to logistical problems in the collection process. The plasma units were stored at 4VC until use.
Methods
Serological tests. All plasma units were tested for HBsAg and antiHBc with commercially available reagent kits (Auszyme and Corzyme, Abbott Laboratories, North Chicago, IL). Tests for antibodies to HCV were performed using the HCV antibody ELISA test system (Ortho Diagnostic Systems, Raritan, NJ) according to the manufacturer's instructions. The mean absorbance value of two positive controls was 1.860 OD units, ofthree negative controls 0.033, and the cutoffwas set at 0.433 (0.400 units above the mean negative control OD). Specimens positive for anti-HCV by ELISA were tested with the anti-HCV recombinant immunoblot assay (RIBA, Ortho Diagnostic Systems). Specimens reactive with C100-3 and 5-1-1 antigens were scored positive, and specimens reactive with only one antigen were scored indeterminate, according to the manufacturer's instructions.
Preparation ofHBV RNA. The complete HBV (adw) genome was cloned into the transcription vector pTZl8U (Bio-Rad Laboratories, Richmond, CA) using standard methods (1 1, 12 After denaturation at 95°C for 5 min, hybridization in solution was carried out for 15 min at 37°C. Hybridized DNA was separated from free probe on an 8% polyacrylamide (acrylamide to bis-acrylamide, 19:1) gel and visualized by autoradiography using XAR-5 film (Eastman Kodak Co., Rochester, NY). The detection limit was 1 pg of amplified HBV 
Results
Serological markers for HBV and HCV in ALT-elevated plasma. 11 of the 101 plasma specimens tested positive for anti-HCV and 4 of the 11 specimens were also positive for anti-HBc. 9 of the 11 anti-HCV ELISA-positive specimens tested positive on the anti-HCV RIBA test, whereas two were indeterminate. Two anti-HCV negative plasmas were positive for anti-HBc, and one of these two was also positive for HBsAg. ization signals of the expected size (-240 bp). The dilutions theoretically containing 20, 2, and 0 molecules of HBV RNA were negative. All HBV RNA dilutions were also amplified for 41 cycles without the RT step and were negative by liquid hybridization, demonstrating that the signal obtained was not generated from undigested HBV DNA used for in vitro transcription.
Detection ofHCVRNA. Pools of three or four RNA specimens, each obtained from 0.6 ml of plasma, were subjected to RT using random primers and then amplified by PCR using either the HCV-specific primer pair JR3-JR4 or PKL 13-PKL14. Ofthe 29 pools generated, three were strongly positive for HCV: pool 11 (containing specimens 31, 32, and 33), pool 12 (containing specimens 34, 35, and 36) and pool D (containing specimens 49, 50, 51, and 52); two pools were weakly positive: pool M (containing specimens 86, 87, 88, and 89), and pool P (containing specimens 97, 98, 99, and 100). In order to identify the source ofthe HCV RNA, individual RNA specimens (from 0.6 ml of plasma), which had been used to A B prepare the PCR-positive pools, were similarly reverse transcribed and analyzed by PCR. HCV sequences were detected with both primer pairs in the anti-HCV-positive specimens 32, 33, 35, 36, 49, 86, and 100; specimen 88 was positive only with PKL1 3-PKL 14, and the remaining anti-HCV-negative specimens used in the pools were negative with both primer pairs. Considering the detection limit of the RT-PCR procedure, we assume that the HCV-PCR-positive RNA specimens contain > 200 target molecules and that RNA specimens with fewer targets would be negative. To determine whether the remaining anti-HCV-positive specimens 28, 37, and 78 harbor HCV in lower concentrations, RNA derived from 2.4 ml of plasma was reverse transcribed and amplified; PCR for these specimens was positive with both HCV-specific primer pairs. These results indicate a strong correlation between the presence of circulating antibodies to the recombinant HCV antigen C100-3, as tested by the anti-HCV ELISA, and the presence of HCV RNA in ALT-elevated plasma from asymptomatic blood donors. Titration ofHCV cDNA preparations. Because we found a significant difference in the signal intensity of the RT-PCR assay for the different specimens, we prepared fourfold serial dilutions of individual cDNA preparations (40 Ml) obtained from a 0.6-ml aliquot of plasma. The cDNA preparations of specimens 32, 33, 86, 88, and 100 showed no PCR signal when diluted (1:4), suggesting that these specimens harbored 2 200 molecules of detectable HCV RNA in 0.6 ml of plasma, but < 200 molecules (detection limit) HCV RNA in 0.15 ml of plasma (Fig. 1 A) . Assuming quantitative recovery of HCV virion RNA by ultracentrifugation and buffer treatment, we calculated that the virus concentration in these specimens is > 3.3 X 102 and < 1.3 X I03 virions/ml of plasma. The cDNA preparations of the strongly positive specimens 35 (Fig. 1 B) , 36 ( Fig. 1 C) , and 49 (data not shown), on the other hand, had endpoint titers of 40,960, 10,240, and 10,240, respectively. With the same assumptions, we calculated viral titers between > 1.3 and < 5.5 X I07 virions/ml for specimen 35 and between 2 3.4 X 106 and < 1.3 X 107 virons/ml for specimen 36 and 49. Plasma specimens 28, 37, and 78 have a calculated virus titer between 2 80 and < 330 virions/ml. Sequence analysis ofHCV cDNA. We sequenced PKL 1 3-PKL 14 amplified HCV cDNAs from the high-titer plasmas 35, 36, and 49 to determine the degree of heterogeneity between different human isolates of HCV in this particular region of the genome. Because most populations of RNA formed direct sequencing of amplified HCV cDNA to obtain nine (GCC) or serine (TO the sequence of the most abundant HCV genome present in tions occurred in the secoi each of the three high-titer plasmas (17) . Sequencing of the tyrosine (TAT) to phenylz cDNA (+) strand was carried out by annealing the upstream amino acid sequence we c amplification primer PKL13 to PKL1 3-PKL14-amplified between the four HCV isola HCV cDNA. For sequencing of the cDNA (-) strand, we chimpanzee-derived and ti annealed the downstream amplification primer PKL14 to in-homologous in this region dependently reverse-transcribed and amplified (Table II) . In all four HCV sequences only one reading frame is continuous. This should (14, 18) , the primer pair PKL1 3-PKL14 anneals within the putative NS3 gene of HCV. This gene has been shown to be relatively conserved among the flaviviruses. The primer pair JR3-JR4 anneals to a less defined region of the HCV genome, which may correspond to the NS2 region ofthe flaviviruses, a region known to display very high rates of sequence divergence (18) . It is possible that mutations in the JR3-JR4 binding sites in this particular isolate interfered with efficient amplification, thus making minute amounts of HCV RNA undetectable. We also note that our negative RT-PCR results on the 90 anti-HCV-negative specimens derive from assays performed on RNA from an equivalent of 0.6 ml of plasma. These results are not, strictly speaking, comparable to the positive RT-PCR results on the three lowest-titer specimens (Nos. 28, 37, and 78), since the three positive RT-PCR results were obtained only when the assay was performed on RNA from 2.4 ml of plasma. Our data do not rule out the possibility that some of the 90 ALT-elevated anti-HCV-negative specimens we studied might harbor HCV at a titer too low for detection in 0.6 ml with our current RT-PCR protocol. However, the strong correlation of our positive RT-PCR results with the anti-HCV results suggests most or all antibodypositive plasma specimens will contain viral RNA detectable by RT-PCR, and as such are likely to be infectious.
After the PCR results were obtained, the anti-HCV RIBA test became available as a proposed confirmatory test for anti-HCV reactivity. We found that two of the 11 (20, 21) .
Because ofthe absence of specific viral markers in the past, quantitation of viral load in NANB/HCV infections could only be performed by dilutional endpoint infectivity testing in chimpanzees (22) , a difficult and expensive procedure. Most investigators have found that human and chimpanzee inocula generally have titers between 102 and 104 chimpanzee infectious doses/ml, although titers of up to 106 have been reported (22) . We used the dilutional endpoint titers of HCV cDNA detection by PCR to calculate the concentration of HCV virions and found between 102 and 5 X 107 virions/ml in the different plasma specimens. In interpreting these data it must be remembered that RT-PCR is at best semiquantitative, even when employed in careful dilutional endpoint titration studies such as ours. In order to calibrate our HCV RT-PCR assay we used cloned HBV RNA; we note that slight differences in RT efficiency and PCR amplification efficiency could have led to differences in final sensitivity of HBV and HCV detection. Furthermore, in view of the high mutation rate characteristic of RNA viruses, RT-PCR performed on field isolates of HCV is also subject to the problem of sequence variation at the primer binding sites which may lead to differential PCR amplification efficiencies. Therefore, our HCV titration figures must be interpreted with caution; we estimate that their margin of error may be as great as plus or minus an order of magnitude. However, we also note that these figures are consistent with those obtained by chimpanzee inoculation, even though RT-PCR does not measure infectivity and nothing is known yet about the possible existence of defective HCV particles.
For a sensitive, specific, and reliable RT-PCR assay, it is important to select primer binding sites which are conserved among different human HCV isolates. The primer pair PKL13-PKLl4 allowed efficient amplification of all HCV cDNA preparations tested so far and therefore we investigated the nucleotide heterogeneity in this particular region of the HCV genome. The sequences of the CH-HCV and the three human HCV isolates are highly homologous, both at the nucleotide level and at the predicted amino acid level, in the region between these two primers.
We conclude that our RT-PCR assay for the detection of HCV sequences in plasma could be useful as a confirmatory test for the diagnosis of HCV infection. It may also provide answers to important questions concerning the natural history of HCV infection, such as frequency and duration of the asymptomatic HCV carrier state.
